Navigation Links
Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
Date:7/23/2012

NEW YORK, July 23, 2012 /PRNewswire/ -- Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer." The trial will be conducted at Memorial Sloan-Kettering Cancer Center in New York City.

(Logo: http://photos.prnewswire.com/prnh/20120404/CL82745LOGO)

Chemotherapy-induced alopecia ("CIA") has been cited as the most disturbing anticipated side effect by the majority of women preparing for chemotherapy, with nearly 10% being at risk of avoiding treatment due to anticipated hair loss. There is currently no treatment available to prevent CIA and causes the patient significant psychological stress and self-awareness of being in a cancer state.  Joaquin J. Jimenez, MD, Associate Professor at the University of Miami Miller School of Medicine, Department of Dermatology & Cutaneous Surgery and an international leader in hair research said, "We have reached a pivotal point in which research meets clinical innovation. There is no doubt that the partnership of Berg Pharma and Memorial Sloan- Kettering will bring us closer to finding a solution for chemotherapy-induced alopecia."

Mario Lacouture, MD, Associate Attending Dermatologist at Memorial Sloan-Kettering Cancer Center and Principal Investigator of the trial, said, "Hair loss can be one of the most devastating side effects of chemotherapy treatment so we are very excited to evaluate this new treatment in the hopes of potentially eliminating or greatly diminishing something that both men and women consider to be a major stigma of many chemotherapeutic treatments."

This Phase I trial has primary objectives of safety and pharmacokinetics and secondary objectives designed to evaluate the ability of the topical drug to prevent or diminish hair loss (alopecia) associated with chemotherapy treatments. Moderate to severe hair loss and hair thinning is a common side effect of many chemotherapeutic agents used to treat cancers. Linda Vahdat, MD, Professor of Medicine, Head, Solid Tumor Service, and Director of the Breast Cancer Research Program at Weill Cornell Medical School said, "The breast cancer research group at Cornell is actively involved in strategies to prevent chemotherapy induced alopecia so we are very excited to see this trial initiated and look forward to its results."

Niven R. Narain, Co-founder, President & CTO of Berg Pharma said, "This is clearly an unmet need in cancer therapy and partnering with a world-class investigator and institution to advance BPM 31543 into clinical development is very exciting.  Berg is committed to treating not only cancer but also the harsh side effects seen with some chemotherapy regimens."

Patient recruitment for the Phase I study had begun at the Evelyn H. Lauder Breast Center at 66th Street and Second Avenue in New York City. Detailed information on patient eligibility can be found at www.clinicaltrials.gov identifier NCT01588522.

About Berg Pharma

Berg Pharma is a Boston based pharmaceutical company and parent company to Berg Biosystems and Berg Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The Company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg Pharma is poised to realize its pursuit of a healthier tomorrow.


'/>"/>
SOURCE Berg Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... Minneapolis MN (PRWEB) , ... April 25, 2017 , ... ... patients and recreational users to dispensaries and head shops –can’t help but be heartened ... loathing for the tell-tale cannabis odor aptly described as “skunk smell.” At last ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
Breaking Medicine News(10 mins):